China's healthcare sector is making steady progress in opening up to foreign investment and expertise, with more than 150 joint-venture and wholly overseas-invested medical institutions now operating nationwide, a senior health official announced Monday.

The 2024 annual reports of major Chinese IVD companies released.

Patients living with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), or multiple sclerosis must see their health practitioners frequently to check the progression of their conditions and their responses

BGI has analyzed the worlds largest set of genome data from pregnant women, a total of 141,431 expectant mothers from across China. The results from the study were published inCell. The genomic analyses from non-invasive prenatal testing (NI

After setting its sights on a $100 million IPO, CAR-T player Allogene Therapeutics has nearly tripled that, pricing the deal at the high end of the range and raising $288 million. Its stock price leaped as high as 39% on its first day of tra

Its hard to believe its been a full year since Abbott closed its acquisition of Alere, considering what a contentious deal it was and how hard Abbott fought last year to get out of it. When the acquisition finally did close, Will All the Abb

Illumina reported recently that its revenues for the third quarter grew 20 percent year over year, driven by growth across its sequencing and microarray products. For the three months ended Sept. 30, the San Diego-based company reported $85

NeoGenomics recently announced a definitive agreement to acquire clinical oncology laboratory Genoptix for $125 million in cash and 1 million shares of NeoGenomics stock. Based in Carlsbad, California, Genoptix specializes on hematology and

Genomics services provider GeneWiz and bioinformatics and genomics company Nashville Biosciences announced recently at the American Society of Human Genetics conference that they are collaborating to combine Nashville Bios BioVU biobank wit

Roche said recently that its diagnostics division revenues grew 6 percent in the first nine months of 2018, driven mainly by growing demand for its immunodiagnostics solutions. For the nine months ended Sept. 30, the Basel, Switzerland-base

Roche said recently that its diagnostics division revenues grew 6 percent in the first nine months of 2018, driven mainly by growing demand for its immunodiagnostics solutions. For the nine months ended Sept. 30, the Basel, Switzerland-base

Thermo Fisher Scientific announced recentlythat it has received CE-IVD marking for its Oncomine Dx Target Test. The next-generation sequencing-based test is designed to detect 46 cancer-driver gene variants associated with approved and inves